Factors influencing survival in sphingosine phosphate lyase insufficiency syndrome: a retrospective cross-sectional natural history study of 76 patients.
SGPL1
Adrenal insufficiency
Gene therapy
Inborn error of metabolism
Kidney transplantation
Nephrotic syndrome
Pyridoxal 5′-phosphate
SPLIS
Vitamin B6
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
28
11
2023
accepted:
06
08
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Sphingosine-1-phosphate lyase insufficiency syndrome (SPLIS) is a recently recognized inborn error of metabolism associated with steroid-resistant nephrotic syndrome as well as adrenal insufficiency and immunological, neurological, and skin manifestations. SPLIS is caused by inactivating mutations in SGPL1, encoding the pyridoxal 5'phosphate-dependent enzyme sphingosine-1-phosphate lyase, which catalyzes the final step of sphingolipid metabolism. Some SPLIS patients have undergone kidney transplantation, and others have been treated with vitamin B6 supplementation. In addition, targeted therapies including gene therapy are in preclinical development. In anticipation of clinical trials, it will be essential to characterize the full spectrum and natural history of SPLIS. We performed a retrospective analysis of 76 patients in whom the diagnosis of SPLIS was established in a proband with at least one suggestive finding and biallelic SGPL1 variants identified by molecular genetic testing. The main objective of the study was to identify factors influencing survival in SPLIS subjects. Overall survival at last report was 50%. Major influences on survival included: (1) age and organ involvement at first presentation; (2) receiving a kidney transplant, and (3) SGPL1 genotype. Among 48 SPLIS patients with nephropathy who had not received a kidney transplant, two clinical subgroups were distinguished. Of children diagnosed with SPLIS nephropathy before age one (n = 30), less than 30% were alive 2 years after diagnosis, and 17% were living at last report. Among those diagnosed at or after age one (n = 18), ~ 70% were alive 2 years after diagnosis, and 72% were living at time of last report. SPLIS patients homozygous for the SPL R222Q variant survived longer compared to patients with other genotypes. Kidney transplantation significantly extended survival outcomes. Our results demonstrate that SPLIS is a phenotypically heterogeneous condition. We find that patients diagnosed with SPLIS nephropathy in the first year of life and patients presenting with prenatal findings represent two high-risk subgroups, whereas patients harboring the R222Q SGPL1 variant fare better than the rest. Time to progression from onset of proteinuria to end stage kidney disease varies from less than one month to five years, and kidney transplantation may be lifesaving.
Sections du résumé
BACKGROUND
BACKGROUND
Sphingosine-1-phosphate lyase insufficiency syndrome (SPLIS) is a recently recognized inborn error of metabolism associated with steroid-resistant nephrotic syndrome as well as adrenal insufficiency and immunological, neurological, and skin manifestations. SPLIS is caused by inactivating mutations in SGPL1, encoding the pyridoxal 5'phosphate-dependent enzyme sphingosine-1-phosphate lyase, which catalyzes the final step of sphingolipid metabolism. Some SPLIS patients have undergone kidney transplantation, and others have been treated with vitamin B6 supplementation. In addition, targeted therapies including gene therapy are in preclinical development. In anticipation of clinical trials, it will be essential to characterize the full spectrum and natural history of SPLIS. We performed a retrospective analysis of 76 patients in whom the diagnosis of SPLIS was established in a proband with at least one suggestive finding and biallelic SGPL1 variants identified by molecular genetic testing. The main objective of the study was to identify factors influencing survival in SPLIS subjects.
RESULTS
RESULTS
Overall survival at last report was 50%. Major influences on survival included: (1) age and organ involvement at first presentation; (2) receiving a kidney transplant, and (3) SGPL1 genotype. Among 48 SPLIS patients with nephropathy who had not received a kidney transplant, two clinical subgroups were distinguished. Of children diagnosed with SPLIS nephropathy before age one (n = 30), less than 30% were alive 2 years after diagnosis, and 17% were living at last report. Among those diagnosed at or after age one (n = 18), ~ 70% were alive 2 years after diagnosis, and 72% were living at time of last report. SPLIS patients homozygous for the SPL R222Q variant survived longer compared to patients with other genotypes. Kidney transplantation significantly extended survival outcomes.
CONCLUSION
CONCLUSIONS
Our results demonstrate that SPLIS is a phenotypically heterogeneous condition. We find that patients diagnosed with SPLIS nephropathy in the first year of life and patients presenting with prenatal findings represent two high-risk subgroups, whereas patients harboring the R222Q SGPL1 variant fare better than the rest. Time to progression from onset of proteinuria to end stage kidney disease varies from less than one month to five years, and kidney transplantation may be lifesaving.
Identifiants
pubmed: 39334450
doi: 10.1186/s13023-024-03311-w
pii: 10.1186/s13023-024-03311-w
doi:
Substances chimiques
Aldehyde-Lyases
EC 4.1.2.-
SGPL1 protein, human
EC 4.1.2.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
355Subventions
Organisme : National Institute of Child Health and Human Development
ID : 1R01HD113778
Informations de copyright
© 2024. The Author(s).
Références
Weaver KN, Sullivan B, Hildebrandt F, et al. Sphingosine phosphate lyase insufficiency syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews. Seattle (WA), 2020.
Choi YJ, Saba JD. Sphingosine phosphate lyase insufficiency syndrome (SPLIS): a novel inborn error of sphingolipid metabolism. Adv Biol Regul. 2019;71:128–40. https://doi.org/10.1016/j.jbior.2018.09.004 .
doi: 10.1016/j.jbior.2018.09.004
pubmed: 30274713
Pournasiri Z, Madani A, Nazarpack F, et al. Sphingosine phosphate lyase insufficiency syndrome: a systematic review. World J Pediatr. 2022. https://doi.org/10.1007/s12519-022-00615-4 .
doi: 10.1007/s12519-022-00615-4
pubmed: 36371483
Tastemel Ozturk T, Canpolat N, Saygili S, et al. A rare cause of nephrotic syndrome-sphingosine-1-phosphate lyase (SGPL1) deficiency: 6 cases and a review of the literature. Pediatr Nephrol. 2023;38(3):711–9. https://doi.org/10.1007/s00467-022-05656-5 .
doi: 10.1007/s00467-022-05656-5
pubmed: 35748945
Yang S, He Y, Zhou J, Yuan H, Qiu L. Steroid-resistant nephrotic syndrome associated with certain SGPL1 variants in a family: Case report and literature review. Front Pediatr. 2023;11:1079758. https://doi.org/10.3389/fped.2023.1079758 .
doi: 10.3389/fped.2023.1079758
pubmed: 36873630
pmcid: 9978203
Maharaj A, Kwong R, Williams J, et al. A retrospective analysis of endocrine disease in sphingosine-1-phosphate lyase insufficiency: case series and literature review. Endocr Connect. 2022. https://doi.org/10.1530/EC-22-0250 .
doi: 10.1530/EC-22-0250
pubmed: 35904228
pmcid: 9346324
Saba JD. Fifty years of lyase and a moment of truth: sphingosine phosphate lyase from discovery to disease. J Lipid Res. 2019;60(3):456–63. https://doi.org/10.1194/jlr.S091181 .
doi: 10.1194/jlr.S091181
pubmed: 30635364
pmcid: 6399507
Van Veldhoven PP. Sphingosine-1-phosphate lyase. Methods Enzymol. 2000;311:244–54.
doi: 10.1016/S0076-6879(00)11087-0
pubmed: 10563331
Atkinson D, Nikodinovic Glumac J, Asselbergh B, et al. Sphingosine 1-phosphate lyase deficiency causes Charcot-Marie-Tooth neuropathy. Neurology. 2017;88(6):533–42. https://doi.org/10.1212/WNL.0000000000003595 .
doi: 10.1212/WNL.0000000000003595
pubmed: 28077491
pmcid: 5304460
Zhao P, Liu ID, Hodgin JB, et al. Responsiveness of sphingosine phosphate lyase insufficiency syndrome to vitamin B6 cofactor supplementation. J Inherit Metab Dis. 2020;43(5):1131–42. https://doi.org/10.1002/jimd.12238 .
doi: 10.1002/jimd.12238
pubmed: 32233035
pmcid: 8072405
Bektas M, Allende ML, Lee BG, et al. Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. J Biol Chem. 2010;285(14):10880–9. https://doi.org/10.1074/jbc.M109.081489 .
doi: 10.1074/jbc.M109.081489
pubmed: 20097939
pmcid: 2856294
Zhao P, Tassew GB, Lee JY, et al. Efficacy of AAV9-mediated SGPL1 gene transfer in a mouse model of S1P lyase insufficiency syndrome. JCI Insight. 2021. https://doi.org/10.1172/jci.insight.145936 .
doi: 10.1172/jci.insight.145936
pubmed: 34877932
pmcid: 8783682
Kihara A. Sphingosine 1-phosphate is a key metabolite linking sphingolipids to glycerophospholipids. Biochim Biophys Acta. 2014;1841(5):766–72. https://doi.org/10.1016/j.bbalip.2013.08.014 .
doi: 10.1016/j.bbalip.2013.08.014
pubmed: 23994042
Uranbileg B, Kurano M, Kano K, et al. Sphingosine 1-phosphate lyase facilitates cancer progression through converting sphingolipids to glycerophospholipids. Clin Transl Med. 2022;12(9):e1056. https://doi.org/10.1002/ctm2.1056 .
doi: 10.1002/ctm2.1056
pubmed: 36125914
pmcid: 9488530
Mitroi DN, Karunakaran I, Graler M, et al. SGPL1 (sphingosine phosphate lyase 1) modulates neuronal autophagy via phosphatidylethanolamine production. Autophagy. 2017;13(5):885–99. https://doi.org/10.1080/15548627.2017.1291471 .
doi: 10.1080/15548627.2017.1291471
pubmed: 28521611
pmcid: 5446076
Mitroi DN, Deutschmann AU, Raucamp M, et al. Sphingosine 1-phosphate lyase ablation disrupts presynaptic architecture and function via an ubiquitin- proteasome mediated mechanism. Sci Rep. 2016;6:37064. https://doi.org/10.1038/srep37064 .
doi: 10.1038/srep37064
pubmed: 27883090
pmcid: 5121647
Alam S, Piazzesi A, Abd El Fatah M, Raucamp M, van Echten-Deckert G. Neurodegeneration caused by S1P-lyase deficiency involves calcium-dependent tau pathology and abnormal histone acetylation. Cells. 2020;9(10):2189. https://doi.org/10.3390/cells9102189 .
doi: 10.3390/cells9102189
pubmed: 32998447
pmcid: 7599816
Kim YI, Park K, Kim JY, et al. An endoplasmic reticulum stress-initiated sphingolipid metabolite, ceramide-1-phosphate, regulates epithelial innate immunity by stimulating beta-defensin production. Mol Cell Biol. 2014;34(24):4368–78. https://doi.org/10.1128/MCB.00599-14 .
doi: 10.1128/MCB.00599-14
pubmed: 25312644
pmcid: 4248733
Elias PM, Williams ML, Crumrine D, Schmuth M. Inherited clinical disorders of lipid metabolism. Curr Probl Dermatol. 2010;39:30–88. https://doi.org/10.1159/000321084 .
doi: 10.1159/000321084
pubmed: 20838037
Behne M, Uchida Y, Seki T, de Montellano PO, Elias PM, Holleran WM. Omega-hydroxyceramides are required for corneocyte lipid envelope (CLE) formation and normal epidermal permeability barrier function. J Investig Dermatol. 2000;114(1):185–92. https://doi.org/10.1046/j.1523-1747.2000.00846.x .
doi: 10.1046/j.1523-1747.2000.00846.x
pubmed: 10620136
Smith CJ, Williams JL, Hall C, et al. Ichthyosis linked to sphingosine 1-phosphate lyase insufficiency is due to aberrant sphingolipid and calcium regulation. J Lipid Res. 2023;64(4):100351. https://doi.org/10.1016/j.jlr.2023.100351 .
doi: 10.1016/j.jlr.2023.100351
pubmed: 36868360
pmcid: 10123262
Bamborschke D, Pergande M, Becker K, et al. A novel mutation in sphingosine-1-phosphate lyase causing congenital brain malformation. Brain Dev. 2018;40(6):480–3. https://doi.org/10.1016/j.braindev.2018.02.008 .
doi: 10.1016/j.braindev.2018.02.008
pubmed: 29501407
Lovric S, Goncalves S, Gee HY, et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest. 2017;127(3):912–28. https://doi.org/10.1172/JCI89626 .
doi: 10.1172/JCI89626
pubmed: 28165339
pmcid: 5330730
Prasad R, Hadjidemetriou I, Maharaj A, et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest. 2017;127(3):942–53. https://doi.org/10.1172/JCI90171 .
doi: 10.1172/JCI90171
pubmed: 28165343
pmcid: 5330744
Atreya KB, Saba JD. Neurological consequences of sphingosine phosphate lyase insufficiency. Front Cell Neurosci. 2022;16:938693. https://doi.org/10.3389/fncel.2022.938693 .
doi: 10.3389/fncel.2022.938693
pubmed: 36187293
pmcid: 9519528
Martin KW, Weaver N, Alhasan K, et al. MRI spectrum of brain involvement in sphingosine-1-phosphate lyase insufficiency syndrome. AJNR Am J Neuroradiol. 2020;41(10):1943–8. https://doi.org/10.3174/ajnr.A6746 .
doi: 10.3174/ajnr.A6746
pubmed: 32855188
pmcid: 7661081
Robinson PN, Kohler S, Bauer S, Seelow D, Horn D, Mundlos S. The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. Am J Hum Genet. 2008;83(5):610–5. https://doi.org/10.1016/j.ajhg.2008.09.017 .
doi: 10.1016/j.ajhg.2008.09.017
pubmed: 18950739
pmcid: 2668030
Khan R, Oskouian B, Lee JY, et al. AAV-SPL 2.0, a modified adeno-associated virus gene therapy agent for the treatment of sphingosine phosphate lyase insufficiency syndrome. Int J Mol Sci. 2023;24(21):15560. https://doi.org/10.3390/ijms242115560 .
doi: 10.3390/ijms242115560
pubmed: 37958544
pmcid: 10648410
Pizzamiglio C, Vernon H, Hanna M, Pitceathly R. Designing clinical trials for rare diseases: unique challenges and opportunities. Nat Rev Methods Primers 2022;2(1)
Administration FaD. Rare diseases: Natural history studies for drug development. Draft guidance for industry: Office of the Commissioner, Office of Clinical Policy and Programs, Office of Orphan Products Development, Center for Druge Evaluation and Research, Center for Biologics Evaluation Research, 2019.
Ranch D. Proteinuria in children. Pediatr Ann. 2020;49(6):e268–72. https://doi.org/10.3928/19382359-20200520-04 .
doi: 10.3928/19382359-20200520-04
pubmed: 32520368
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. https://doi.org/10.1038/gim.2015.30 .
doi: 10.1038/gim.2015.30
pubmed: 25741868
pmcid: 4544753
Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35(11):1978–80. https://doi.org/10.1093/bioinformatics/bty897 .
doi: 10.1093/bioinformatics/bty897
pubmed: 30376034
Sedillo J, Badduke C, Schrodi S, et al. Prevalence estimate of sphingosine phosphate lyase insufficiency syndrome in worldwide and select populations. Genet Med Open. 2024;2:100840.
doi: 10.1016/j.gimo.2023.100840
Spizzirri AP, Cobenas CJ, Suarez ADC. A rare cause of nephrotic syndrome - sphingosine-1-phosphate lyase (SGPL1) deficiency: 2 cases. Pediatr Nephrol. 2023;38(1):307–8. https://doi.org/10.1007/s00467-022-05716-w .
doi: 10.1007/s00467-022-05716-w
pubmed: 35997975
Saygili S, Canpolat N, Sever L, Caliskan S, Atayar E, Ozaltin F. Persistent hypoglycemic attacks during hemodialysis sessions in an infant with congenital nephrotic syndrome: answers. Pediatr Nephrol. 2019;34(1):77–9. https://doi.org/10.1007/s00467-018-3982-7 .
doi: 10.1007/s00467-018-3982-7
pubmed: 29959533
Seven Menevse T, Kendir Demirkol Y, Gurpinar Tosun B, et al. Steroid hormone profiles and molecular diagnostic tools in pediatric patients with non-CAH primary adrenal insufficiency. J Clin Endocrinol Metab. 2022;107(5):e1924–31. https://doi.org/10.1210/clinem/dgac016 .
doi: 10.1210/clinem/dgac016
pubmed: 35028661
Pezzuti IL, Silva IN, Albuquerque CT, Duarte MG, Silva JM. Adrenal insufficiency in association with congenital nephrotic syndrome: a case report. J Pediatr Endocrinol Metab. 2014;27(5–6):565–7. https://doi.org/10.1515/jpem-2011-0296 .
doi: 10.1515/jpem-2011-0296
pubmed: 24633749
Linhares N, Arantes R, Araujo S, Pena S. Nephrotic syndrome and adrenal insufficiency caused by a variant in SGPL1. Clin Kidney J. 2017;11:1–6.
Janecke AR, Xu R, Steichen-Gersdorf E, et al. Deficiency of the sphingosine-1-phosphate lyase SGPL1 is associated with congenital nephrotic syndrome and congenital adrenal calcifications. Hum Mutat. 2017;38(4):365–72. https://doi.org/10.1002/humu.23192 .
doi: 10.1002/humu.23192
pubmed: 28181337
pmcid: 5384969
Settas N, Persky R, Faucz FR, et al. SGPL1 deficiency: a rare cause of primary adrenal insufficiency. J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-02238 .
doi: 10.1210/jc.2018-02238
pmcid: 6435096
Roa-Bautista A, Sohail M, Wakeling E, et al. Combined novel homozygous variants in both SGPL1 and STAT1 presenting with severe combined immune deficiency: case report and literature review. Front Immunol. 2023;14:1186575. https://doi.org/10.3389/fimmu.2023.1186575 .
doi: 10.3389/fimmu.2023.1186575
pubmed: 37377976
pmcid: 10291229
Najafi M, Riedhammer KM, Rad A, et al. High detection rate for disease-causing variants in a cohort of 30 Iranian pediatric steroid resistant nephrotic syndrome cases. Front Pediatr. 2022;10:974840. https://doi.org/10.3389/fped.2022.974840 .
doi: 10.3389/fped.2022.974840
pubmed: 36245711
pmcid: 9555279
Ron HA, Scobell R, Strong A, Salazar EG, Ganetzky R. Congenital adrenal calcifications as the first clinical indication of sphingosine lyase insufficiency syndrome: a case report and review of the literature. Am J Med Genet A. 2022;188(11):3312–7. https://doi.org/10.1002/ajmg.a.62956 .
doi: 10.1002/ajmg.a.62956
pubmed: 35972040
pmcid: 9548492
Mathew G, Yasmeen MS, Deepthi RV, et al. Infantile nephrotic syndrome, immunodeficiency and adrenal insufficiency-a rare cause: answers. Pediatr Nephrol. 2022;37(4):817–9. https://doi.org/10.1007/s00467-021-05377-1 .
doi: 10.1007/s00467-021-05377-1
pubmed: 34999987
Mathew G, Yasmeen MS, Deepthi RV, et al. Infantile nephrotic syndrome, immunodeficiency and adrenal insufficiency-a rare cause: questions. Pediatr Nephrol. 2022;37(4):813–5. https://doi.org/10.1007/s00467-021-05357-5 .
doi: 10.1007/s00467-021-05357-5
pubmed: 34999981
Buyukyilmaz G, Adiguzel KT, Aksoy OY, et al. Novel sphingosine-1-phosphate lyase mutation causes multisystemic diseases: case report. Turk J Pediatr. 2023;65(6):1025–32. https://doi.org/10.24953/turkjped.2022.187 .
doi: 10.24953/turkjped.2022.187
pubmed: 38204317
Tran P, Jamee M, Pournasiri Z, Chavoshzadeh Z, Sullivan KE. SGPL1 deficiency: nephrotic syndrome with lymphopenia. J Clin Immunol. 2022. https://doi.org/10.1007/s10875-022-01348-9 .
doi: 10.1007/s10875-022-01348-9
pubmed: 36050428
pmcid: 8976534
Taylor VA, Stone HK, Schuh MP, Zhao X, Setchell KD, Erkan E. Disarranged sphingolipid metabolism from sphingosine-1-phosphate lyase deficiency leads to congenital nephrotic syndrome. Kidney Int Rep. 2019;4(12):1763–9. https://doi.org/10.1016/j.ekir.2019.07.018 .
doi: 10.1016/j.ekir.2019.07.018
pubmed: 31844815
pmcid: 6895586
Reiss U, Oskouian B, Zhou J, et al. Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. J Biol Chem. 2004;279(2):1281–90.
doi: 10.1074/jbc.M309646200
pubmed: 14570870
Bierzynska A, McCarthy HJ, Soderquest K, et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int. 2017;91(4):937–47. https://doi.org/10.1016/j.kint.2016.10.013 .
doi: 10.1016/j.kint.2016.10.013
pubmed: 28117080
Saba JD, Keller N, Wang JY, Tang F, Slavin A, Shen Y. Genotype/phenotype interactions and first steps toward targeted therapy for sphingosine phosphate lyase insufficiency syndrome. Cell Biochem Biophys. 2021;79(3):547–59. https://doi.org/10.1007/s12013-021-01013-9 .
doi: 10.1007/s12013-021-01013-9
pubmed: 34133011